(2E)-3-(2-methoxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one, 95.0%, 10g

3-(3,4-Difluorophenoxy)pyrrolidine hydrochloride, 98%, 250mg

(+/-)-1-N-Boc-3-Cyano-piperidine, 99.0%, 5g

Methylmaleic Hydrazide>98.0%(GC)5g

2-(3-cyclopropyl-6-oxo-1,6-dihydropyridazin-1-yl)propanoic acid, 95.0%, 250mg

ethyl 1-(aminomethyl)-3-methylbutylcarbamate, 95.0%, 1g

(4R,4'R)-2,2'-(Cyclopropane-1,1-diyl)bis(4-(tert-butyl)-4,5-dihydrooxazole), 97%, 100mg

GC-Kapillarsäule ROTI®Cap-1 MS, 60 m, 0.32 mm, 0.25 µm, unpolar, 1 Stück

2,2-Dimethyl-5-(propan-2-ylidene)-1,3-dioxane-4,6-dione, 95.0%, 250mg

4-(Difluoromethoxy)benzenesulfonyl chloride, 95.0%, 5g

[trans-3-(benzyloxy)cyclobutyl]acetonitrile, 95.0%, 1g

N-(2-chlorobenzyl)-3-oxobutanamide, 95.0%, 5g

4-benzoyl-8-methyl-1-oxa-4-azaspiro[4.5]decane-3-carboxylic acid, 95.0%, 2g